LIBERTY's robotic endovascular system doubling revenue each quarter; survival to self-sustaining scale without dilution is the unresolved condition

Microbot Medical is a commercial-stage medical device company whose lead product, LIBERTY, is an FDA-approved robotic system for peripheral endovascular procedures.

LIBERTY, cleared by FDA in September 2025 as a single-use robotic system for peripheral endovascular procedures, has expanded to eight U.S. sales territories, secured a federal distribution agreement covering 2,000-plus government facilities, and added a second manufacturing site via Sanmina. Revenue more than doubled from Q1 to Q2 2026, driven by repeat orders and new health system adoptions across seven states. With cash and burn data undisclosed, the critical open question is whether commercial momentum generates sufficient revenue to fund operations before the company requires dilutive financing.